The current path to CAR-T cell therapy is, by any measure, a logistical ordeal. A patient’s immune cells must be drawn out of the body, shipped to a specialized facility, genetically reprogrammed, ...
The industrial food matrix is not merely delivering poor nutrition. It is executing a systemic epigenetic intervention on human gene expression, suppressing tumor-suppressor pathways, destabilizing ...
“If successful in harnessing DNA instructions and a proprietary delivery platform to reprogram the immune system, Adimune has the potential to lead a new era of addressing diseases through programming ...
In the intricate regulation of inflammation, metabolic reprogramming and posttranslational modification (PTM) have emerged as pivotal players, offering new avenues for understanding the fine-tuned ...
The first cell rejuvenation therapy is set to enter clinics, testing if aging cells can be reset to a younger, healthier ...
Plans to seek FDA submission and approval for first-in-human trials in type 1 diabetes and stiff person syndrome targeted for early 2026 MOUNTAIN VIEW, Calif.--(BUSINESS WIRE)-- Aditxt, Inc. (NASDAQ: ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results